JACC:evolocumab治疗家族性高胆固醇血症的远期预后研究

2020-02-21 不详 MedSci原创

对不能达到低密度脂蛋白胆固醇(LDL-C)目标的家族性高胆固醇血症(FH)患者,前蛋白转化酶-枯草杆菌蛋白酶9抑制剂治疗是一种治疗选择。本研究的目的旨在评估evolocumab对纯合FH或严重杂合FH患者的远期有效性和安全性。本研究纳入分析了300名接受evolocumab治疗的患者(纯合FH为106名),经过平均4.1年时间的随访,有89.3%的患者发生了不良反应时间,最常见的是鼻咽炎、流感、上

对不能达到低密度脂蛋白胆固醇(LDL-C)目标的家族性高胆固醇血症(FH)患者,前蛋白转化酶-枯草杆菌蛋白酶9抑制剂治疗是一种治疗选择。本研究的目的旨在评估evolocumab对纯合FH或严重杂合FH患者的远期有效性和安全性。

本研究纳入分析了300名接受evolocumab治疗的患者(纯合FH为106名),经过平均4.1年时间的随访,有89.3%的患者发生了不良反应时间,最常见的是鼻咽炎、流感、上呼吸道感染和头疼。LDL-C的平均变化比例在纯合FH和严重杂合FH患者中分别为-21.2% (-59.8 mg/dl) 和-54.9% (-104.4 mg/dl)。心血管事件发生率为2.7%每年。

研究结果显示,对于纯合FH和严重杂合FH患者而言,evolocumab具有较高的长期安全性,可有效降低低密度脂蛋白胆固醇水平。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
    2020-12-23 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
    2021-01-19 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1912308, encodeId=aea61912308db, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Dec 23 03:02:00 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854658, encodeId=e8221854658c6, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Jan 19 09:02:00 CST 2021, time=2021-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984391, encodeId=75bb198439100, content=<a href='/topic/show?id=c4bb9443038' target=_blank style='color:#2F92EE;'>#远期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94430, encryptionId=c4bb9443038, topicName=远期预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Wed Jun 17 08:02:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326489, encodeId=1aaa132648904, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380091, encodeId=d75e13800914e, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426482, encodeId=1a1c142648238, content=<a href='/topic/show?id=96fae1243b' target=_blank style='color:#2F92EE;'>#Evolocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7124, encryptionId=96fae1243b, topicName=Evolocumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce534073393, createdName=ZGMFX25A, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629565, encodeId=247b162956547, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Sun Feb 23 03:02:00 CST 2020, time=2020-02-23, status=1, ipAttribution=)]
    2020-02-23 wetgdt

相关资讯

JACC:外周动脉血运重建术后远期的预后研究

目前,对于外周动脉疾病血运重建后的远期心血管和四肢结局尚不清楚。本研究的目的旨在描述外周血运重建后的远期预后以及评估术后主要不良肢体事件(MALE)住院治疗与后续不良事件的相关性。本研究纳入分析了393017名接受了血运重建的外周动脉疾病患者,经过平均2.7年时间的随访,心梗或卒中的累积发病率为9.8%,共有50750名患者有过至少一次MALE住院治疗。术后的MALE住院治疗与更高的心梗或卒中风险

JACC:肠球菌心内膜炎的当代临床研究

肠球菌心内膜炎(EE)在西方国家中逐渐增多,然而却缺乏大型临床研究数据。本研究的目的旨在描述GAMES临床研究中的EE临床特征及其预后因素。本研究纳入分析了516例EE患者和3308例非肠球菌心内膜炎(NEE)患者作为对照。分析结果显示,EE患者年龄更大、慢性肺疾病更多、慢性心衰更多,更易有心内膜炎史和退行性瓣膜疾病。EE患者更常伴有主动脉瓣假体,急性心衰发生风险更高,但起搏器和除颤仪器植入的概率

盘点:JACC2月第二期研究一览

1. 冠脉CTA可排除有临床意义的非ST段抬高型心梗患者DOI: 10.1016/j.jacc.2019.12.012http://www.onlinejacc.org/content/75/5对于非ST段抬高型急性冠脉综合征(NSTEACS)患者,冠脉的病理解剖从结构正常血管到严重的冠脉损伤不等。本研究的目的旨在评估冠状动脉ct血管造影(CTA)是否能排除冠脉狭窄≥50%的NSTEACS患者。本

JACC: 长期暴露于高浓度大气PM2.5,心血管疾病风险显著增加

大气细颗粒物(PM2.5)污染导致的健康危害广受关注,但是由于我国大气污染监测网络建成较晚,大气长期污染对我国人群心血管疾病发病和死亡的危害缺乏较为明确的人群证据。

ACC: 疫情下心血管病患者的BB应用思考

2020年2月13日,美国心脏病学学会(ACC)就新型冠状病毒对心脏的影响发布临床公告,指出心血管病(CVD)患者是感染新型冠状病毒的高危人群,并给予9项指导建议,包括在疫情爆发期间,建议继续规范服用他汀、β受体阻滞剂(BB)、血管紧张素转换酶抑制剂(ACEI)和阿司匹林等稳定斑块,提供心脏保护

JACC:结合珠蛋白基因型会影响强化降糖治疗对心血管预后的影响

糖化血红蛋白与心血管疾病风险是否存在直接相关性尚存争议。结合珠蛋白(Hp)基因位点的常见多态性在高血糖的情况下与心血管疾病发生相关,尤其是冠心病。本研究旨在确定在ACCORD(糖尿病心血管风险控制措施)研究中,强化降糖治疗与标准降糖治疗对心血管疾病风险的治疗差异是否取决于Hp表型。本研究对ACCORD临床研究中的5806名参与者进行了Hp基因型的鉴定,与标准治疗相比,强化治疗在Hp2-2患者中与更